2011～2013年南京市样本医院抗肿瘤抗生素应用现状和趋势分析

Status and Tendency of Anticancer Antibiotics from 2011 to 2013 in Nanjing Sample Hospitals

目的：评价南京地区27家样本医院2011~2013年抗肿瘤抗生素使用情况及特点，了解抗肿瘤抗生素治疗新理念和应用新药的新途径。方法：用限定日剂量法（DDDs）分析2011~2013年样本医院抗肿瘤抗生素应用的品种、数量、金额、日均用量数（DDDs）及日均费用（DDC）等情况。结果：抗肿瘤抗生素销售金额及销量逐年上升，最常用的是蒽环类抗肿瘤抗生素，已成为抗肿瘤抗生素的主体，销售金额排名前几位的药物主要是表柔比星、伊达比星、吡柔比星和阿霉素；DDDs排名前几位的药物主要是表柔比星、吡柔比星、丝裂霉素和阿霉素。大多数抗肿瘤抗生素的销量与使用同步性良好。结论：抗肿瘤抗生素的需求量逐年增加，尤其是蒽环类药物成为抗肿瘤抗生素的主流药物。

Objective： To comprehend the new therapeutic idea and way of using new drugs by estimating the using situation of anticancer antibiotics from 2011 to 2013 in 27 sample hospitals of Nanjing. Methods： With the method of defined daily dose （DDDs）, the use of anticancer antibiotics was analyzed in respect of drug categories, consumption quantity, sales amount, DDDs and defined daily consumption （DDC）, etc., from 2011 to 2013 in 27 sample hospitals. Results： The sales amount of anticancer antibiotics increased year by year, and the most commonly used drugs were antharcycline. The top four sales amounts were pharmorubicin, idarubicin, pirarubicin and adriamycin, the top four DDDs were pharmorubicin, pirarubicin, mitomycin and adriamycin. Most of the anticancer antibiotics sales amounts and the DDDs were concordant. Conclusion： The demand of anticancer antibiotics increased year by year. They have broad development prospects, especially antharcycline will become the leading anticancer antibiotics..